2025年《国家基本医疗保险、生育保险和工伤保险药品目录》和首版《商业健康保险创新药品目录》日 前正式发布。新版药品目录新增114种药品，调整后医保药品目录内药品总数增至3253种，其中西药 1857种、中成药1396种。肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显 提升。 值得一提的是，此次医保新增药品中，1类创新药数量达50种，再创历史新高。这批创新药囊括多款"全 球首创""首个国产"的明星品种，覆盖国内外多家主流创新药企，让临床急需的突破性疗法更快惠及患 者。 在跨国药企方面，诺华共有2个新产品及4个新适应证成功纳入新版医保目录，长效"降脂针"英克司兰钠 注射液(乐可为)位列其中，自2017年以来，该公司已有40余款药物进入国家医保目录；强生创新制药旗 下三款创新药物特诺雅达、特诺雅及泽倍珂也成功入围，覆盖克罗恩病、溃疡性结肠炎、前列腺癌等重 大疾病领域，目前其在华上市的40款创新药品中，已有34款被纳入医保，惠及大批患者。 在国内药企方面，恒瑞医药（600276）共有11款抗肿瘤产品纳入新版医保目录，涵盖5款首次入保的创 新产品、3款创新药的关键新适应症，以及3款重点产品的目录 ...

Core Viewpoint - Sanofi has decided to cease the promotion of its cholesterol-lowering drug, Polatad (Alirocumab injection), in the Chinese market due to global supply issues and a shift in its cardiovascular market strategy [1][6]. Market Dynamics - The PCSK9 market is becoming increasingly competitive, with more domestic alternatives being included in the National Medical Insurance Drug List, leading to a more diversified market [6][7]. - Polatad's market share has been significantly eroded by competitors, with sales figures showing a rise in sales for rival products like Repatha (from 130 million yuan to 1.323 billion yuan) while Polatad's sales increased from 17 million yuan to 629 million yuan during the same period [7]. Patient Impact - Patients using Polatad have expressed minimal concern regarding its withdrawal, indicating that they can easily switch to alternative medications without significant issues [2][5]. - Clinical experts have noted that the mechanism of action for PCSK9 inhibitors is similar across different products, suggesting that patients can transition between these medications without adverse effects [4][8]. Clinical Alternatives - Multiple alternatives to Polatad are available, including Repatha and domestic products like Xinbile (Torlipressin) and other PCSK9 monoclonal antibodies, which have been approved and are effective in lowering LDL-C levels [6][8]. - The introduction of new therapies, such as Novartis's siRNA drug inclisiran, which offers a more convenient dosing schedule, further enhances the options available for patients [8].